Clinical trials: Diabetes Mellitus Type 1 or 2
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes
This trial is conducted in Asia, Europe and Oceania. The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart) with biphasic insulin aspart 30 in subjects with type 2 diabetes.
- Trial name
- BOOST™ (NCT01009580)
- Testing
- insulin degludec/insulin aspart, biphasic insulin aspart 30
- Where
- 53 sites in Australia, Denmark and 8 more
- Volunteers
- 447 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Insulin Glargine "All to Target" Trial
The primary objectives were: To demonstrate the superiority of Lantus plus stepwise addition of mealtime Apidra® (Lantus/Apidra-3) versus twice-daily Premixed insulin based on the proportion of patients achieving target glycemic…
- Trial name
- NCT00384085
- Testing
- Insulin Glulisine, Insulin Glargine, Premixed Insulin
- Where
- United States
- Volunteers
- 588 people
- Sponsor
- Sanofi
Pain, Diabetic Neuropathies
A Research Study of V3381 for the Treatment of Diabetic Peripheral Neuropathic Pain
The objective of this study is to investigate the safety and efficacy of an investigational drug, V3381, for the treatment of diabetic peripheral neuropathic (DPN) pain (pain in one's feet and legs, or even in one's hands and…
- Trial name
- NCT00375960
- Testing
- V3381
- Where
- 6 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Vernalis (R&D) Ltd
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes
Fast-acting insulin aspart (faster aspart) will be tested to see how well it works and if it is safe. The study compares 2 medicines for type 1 and type 2 diabetes - faster aspart (a new medicine) and insulin aspart (a medicine…
- Trial name
- NCT04588259
- Testing
- Faster aspart, Insulin aspart, Insulin degludec
- Where
- 40 sites in China, Hong Kong
- Volunteers
- 331 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Local Registration Trial in China Humalog Mix 50
The primary objective of this study is to compare the 2-hour PPBG excursion following a standard test meal in insulin-requiring diabetic patients treated twice daily with human insulin mix 50/50, versus the 2-hour PPBG excursion…
- Trial name
- NCT00191581
- Testing
- Humalog Mix 50, Human Insulin Mix 50:50
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus
The purpose of the study is to compare Humalog (Insulin lispro)-recombinant human hyaluronidase (rHuPH20) or Novolog (Insulin aspart)-rHuPH20 to Humalog (Insulin lispro) for the treatment of Type 1 Diabetes Mellitus (T1DM) in…
- Trial name
- NCT01194245
- Testing
- Insulin lispro, recombinant human hyaluronidase PH20, Insulin aspart
- Where
- 19 sites in United States
- Volunteers
- 135 people
- Sponsor
- Halozyme Therapeutics
Obesity, Overweight
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
This study will evaluate the efficacy and safety of AZD6234 compared with placebo in adults who are overweight or obese, with or without type 2 diabetes mellitus.
- Conditions
- Obesity, Overweight, Type 2 Diabetes Mellitus
- Trial name
- SELENE-Asia (NCT07922330)
- Testing
- AZD6234
- Where
- 34 sites in China, India
- Volunteers
- 330 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes
This trial is conducted in Asia. The aim of the trial is to investigate safety and efficacy of semaglutide once weekly in monotherapy or in combination with one OAD (oral anti-diabetic drug) in Japanese subjects with type 2…
- Trial name
- SUSTAIN™ (NCT02207374)
- Testing
- semaglutide, DPP-4 inhibitor
- Where
- 43 sites in Japan
- Volunteers
- 601 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin degludec (IDeg) and liraglutide (Lira) in subjects with type 2 diabetes.
- Trial name
- DUAL™ I (NCT01336023)
- Testing
- insulin degludec/liraglutide, insulin degludec, liraglutide
- Where
- 302 sites in United States, Australia and 18 more
- Volunteers
- 1,663 people
- Sponsor
- Novo Nordisk A/S
Metastatic Colorectal Cancer
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
This is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab or standard-of-care treatments in…
- Trial name
- NCT05608044
- Testing
- Botensilimab, Balstilimab, Standard of Care
- Where
- 65 sites in United States, Belgium and 6 more
- Volunteers
- 234 people
- Sponsor
- Agenus Inc.
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Pharmacokinetics/Dynamics of Basal (Continuous) Insulin Infusion Administered Either Intradermally or Subcutaneously
The primary objective of this study will be to assess the PK/PD responsiveness of basal ID administered insulin compared to SC, and to determine the safety and local tolerability of extended (two six-hour periods) microneedle…
- Trial name
- NCT01061216
- Testing
- Intradermal insulin delivery: BD Research Catheter Set, Subcutaneous insulin delivery:ACCU-CHEK Rapid-D Infusion Set
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Becton, Dickinson and Company
Diabetic Foot Ulcer, Type 1 Diabetes Mellitus
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
The goal of this investigational study is to evaluate the safety and clinical performance of Tropocells Autologous Platelet-rich Fibrin (PRF) for wound care for both males and females, ages 18-80 years old, with Grade 1 and 2…
- Conditions
- Diabetic Foot Ulcer, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus (T2DM), Neuroischemic Foot Ulcer
- Trial name
- NCT06810726
- Testing
- Platelet Rich Plasma
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Estar Medical dba Medical Technologies, LTD
Type 1 Diabetes, Type 2 Diabetes
A Trial of 18F-AV-133 Positron Emission Tomography (PET)
The purpose of this study is to evaluate the safety and pancreas imaging properties of 18F-AV-133.
- Trial name
- NCT01515384
- Testing
- 18F-AV-133
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Diabetes Mellitus
Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus
This is a safety and dose finding efficacy study to evaluate the effects of BGP-15 over the dose range of 100 mg/day to 400 mg/day.
- Trial name
- NCT01069965
- Testing
- BGP-15 100 mg QD, BGP-15 100 mg BID, BGP-15 200 mg QD
- Where
- 30 sites in United States, Germany and 1 more
- Volunteers
- 196 people
- Sponsor
- N-Gene Research Laboratories, Inc.
Diabetes, Type 1, Diabetes, Type 2
Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes
Pulmonary Safety in Diabetics with T/I
- Trial name
- NCT00308737
- Testing
- Technosphere® Insulin Inhalation Powder, Usual Care
- Where
- 176 sites in United States, Canada and 6 more
- Volunteers
- 2,053 people, healthy volunteers welcome
- Sponsor
- Mannkind Corporation
Type 2 Diabetes Mellitus
Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus
In this randomized, double-blind, double-dummy, placebo-controlled study, approximately 675 eligible subjects with type 2 diabetes and inadequate control on at least one and up to 3 oral glucose-lowering agents will undergo an…
- Trial name
- NCT04606576
- Testing
- ORMD-0801 QD, ORMD-0801 BD
- Where
- United States
- Volunteers
- 710 people
- Sponsor
- Oramed, Ltd.
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes
This trial is conducted in Africa, Asia and Europe. The aim of the trial is to compare the efficacy and safety of insulin degludec/insulin aspart and BIAsp 30 (biphasic insulin aspart 30) in insulin naïve subjects with type 2…
- Trial name
- BOOST™ (NCT01513590)
- Testing
- insulin degludec/insulin aspart
- Where
- 49 sites in Algeria, Bulgaria and 8 more
- Volunteers
- 394 people
- Sponsor
- Novo Nordisk A/S
Diabetic Nephropathy
Effect of Pyridorin in Patients With Diabetic Nephropathy
The primary objective of the study is to evaluate the safety and tolerability of Pyridorin (pyridoxamine dihydrochloride) 50 mg given orally twice daily in patients with diabetic kidney disease.
- Trial name
- NCT00320060
- Testing
- Pyridorin (pyridoxamine dihydrochloride)
- Volunteers
- 128 people
- Sponsor
- BioStratum
Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus
Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System
This multi-center, randomized, cross-over trial will evaluate the efficacy of the Omnipod 6 System compared with the Omnipod 5 System in individuals with type 1 or type 2 diabetes and suboptimal glycemia.
- Trial name
- STRIVE 2 (NCT07579702)
- Testing
- Omnipod 5 System, Omnipod 6 System
- Where
- 11 sites in United States
- Volunteers
- 200 people
- Sponsor
- Insulet Corporation
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Anxiety about needles is a concern commonly expressed by diabetics when beginning insulin therapy. A shorter, thinner pen needle that delivers insulin with the safety and efficacy profile of longer pen needles may appeal to many…
- Trial name
- NCT01231984
- Testing
- 4 mm x 32G Pen Needle, 8mm x 31G Pen Needle, 12.7mm x 29G Pen Needle
- Where
- 10 sites in United States
- Volunteers
- 293 people
- Sponsor
- Becton, Dickinson and Company